title: A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA)
abstract: OBJECTIVE
  To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer.
  
  
  METHODS
  Retrospective analysis.
  
  
  METHODS
  Regional cancer treatment center.
  
  
  METHODS
  Forty-four previously untreated patients with metastatic colorectal cancer in a phase I-II trial of PALA-fluorouracil.
  
  
  RESULTS
  One or more transient hepatic abnormalities frequently occurred in 15 of the 17 responding patients. Within the first 10 weeks of treatment, 5 patients developed ascites, 12 had a decrease in the serum albumin level, 6 developed bilirubin elevations, and 7 had transaminase elevations, all in the presence of a complete or partial tumor response. Prolongations of the prothrombin time and elevations of serum glucose levels were also seen.
  
  
  CONCLUSIONS
  An unusual syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia is associated with a PALA-fluorouracil regimen. These abnormalities, which may be related to decreased hepatic protein synthesis, occurred more often in patients whose tumor was responding to chemotherapy. Clinicians must recognize that in patients undergoing chemotherapy with these agents, ascites and elevated liver function tests may be secondary to drug administration and are not necessarily due to disease progression.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: N
authors.initials: N
authors.lastname: Kemeny
authors.forename: K
authors.initials: K
authors.lastname: Seiter
authors.forename: D
authors.initials: D
authors.lastname: Martin
authors.forename: C
authors.initials: C
authors.lastname: Urmacher
authors.forename: D
authors.initials: D
authors.lastname: Niedzwiecki
authors.forename: R C
authors.initials: RC
authors.lastname: Kurtz
authors.forename: P
authors.initials: P
authors.lastname: Costa
authors.forename: M
authors.initials: M
authors.lastname: Murray
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001201:Ascites / Q000139:chemically induced*; D001224:Aspartic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy; D004341:Drug Evaluation; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D010746:Phosphonoacetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D011517:Prothrombin Time; D012189:Retrospective Studies; D012709:Serum Albumin / Q000172:deficiency* / Q000187:drug effects; D013577:Syndrome; D000637:Transaminases / Q000187:drug effects
chemical_list: D012709:Serum Albumin; D001224:Aspartic Acid; C013195:sparfosic acid; D000637:Transaminases; D010746:Phosphonoacetic Acid; D005472:Fluorouracil